Product Information
MARAVIROC 300 MG TABLET is a generic product labeled by i3 Pharmaceuticals, LLC, priced at $6.3391 per EA under NDC 72319002502. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Aug 17, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
i3 Pharmaceuticals, LLCNDC
72319002502
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MARAVIROCApproval Type
Generic (ANDA)
FDA Application
ANDA217114FDA Approved
8/17/2023
TE Code
AB
On Market Since
9/15/2023
Pharmacological Classes
Price Statistics
The NADAC for MARAVIROC 300 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 69.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.3391 per EA |
|---|---|
| All-time high | $20.8330 (Jun 12, 2024) |
| All-time low | $6.2876 (Aug 19, 2026) |
| 52-week high | $11.1701 |
| 52-week low | $6.2876 |
| Median price | $16.6350 |
| Average price | $14.4826 |
| Largest weekly change | -22.9% (Sep 17, 2025) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
i3 Pharmaceuticals, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Maraviroc market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
CCR5 Co-receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MARAVIROC 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MARAVIROC 300 MG TABLET, manufactured by i3 Pharmaceuticals, LLC, is $6.3391 per EA (NDC 72319002502), effective Sep 30, 2026.
How has the price of MARAVIROC 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for MARAVIROC 300 MG TABLET has declined 69.3%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for MARAVIROC 300 MG TABLET?
Since Apr 17, 2024, the NADAC for MARAVIROC 300 MG TABLET has ranged from a low of $6.2876 (Aug 19, 2026) to a high of $20.8330 (Jun 12, 2024), with a median of $16.6350 per EA.
Are there cheaper alternatives to MARAVIROC 300 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MARAVIROC 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures MARAVIROC 300 MG TABLET?
MARAVIROC 300 MG TABLET (NDC 72319002502) is labeled by i3 Pharmaceuticals, LLC, and CMS classifies it as a generic product.